Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1991
Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's diseaseR T Silver, D C Case, R H Wheeler, et al.
Investigational New Drugs|January 1, 1986
Recombinant gamma interferon in advanced breast cancer: a phase II trialH B Muss, M Caponera, P J Zekan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1985
Single agent vincristine by infusion in refractory multiple myelomaD V Jackson, L D Case, E K Pope, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF). A clinical trial of the Piedmont Oncology Association (POA)S K Shipp, H B Muss, M A Westrick, et al.
Cancer|February 15, 1985
A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim reportJ M Sterchi, H B Wells, L D Case, et al.
Cancer|June 15, 1981
A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancerM R Cooper, A L Rhyne, H B Muss, et al.
Insect Molecular Biology|January 25, 2005
Expression of Cyp6g1 and Cyp12d1 in DDT resistant and susceptible strains of Drosophila melanogasterR A Festucci-Buselli, A S Carvalho-Dias, M de Oliveira-Andrade, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Clinical trial of folinic acid to reduce vincristine neurotoxicityD V Jackson, R A McMahan, E K Pope, et al.
Cancer|December 1, 1982
Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil in advanced breast cancer: a randomized trial of the Piedmont Oncology AssociationH B Muss, F Richards, D V Jackson, et al.
Cancer|June 15, 1981
Combination chemotherapy with and without the methanol-extracted residue of bacillus Calmette-Guerin (MER) in extensive non-small-cell lung cancer: a prospective randomized study for the Piedmont Oncology AssociationF Richards, V Howard, A Shore, et al.
Pageof 10